Evidence map›Paper›PMID 40632377›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

Intravenous combined with nebulized polymyxin B may be effective in treating carbapenem-resistant gram-negative bacilli hospital-acquired pneumonia: a retrospective cohort study.

Ye Zhang, Jiangtao Chen, Lexin Fang, Min Wang, Wenqing Zeng, Yueping Ding

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ye Zhang *Department of Pharmacy, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou, China.
Jiangtao Chen *Department of Intensive Care Unit, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou, China.
Lexin Fang *Department of Intensive Care Unit, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou, China.
Min Wang *Department of Pharmacy, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou, China.
Wenqing ZengDepartment of Intensive Care Unit, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou, China.
Yueping DingDepartment of Intensive Care Unit, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou, China. Dingyp0424@zcmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the clinical efficacy and safety of intravenous polymyxin B versus the combination of intravenous and nebulized polymyxin B for treating carbapenem-resistant gram-negative bacilli hospital-acquired pneumonia (CRGNB-HAP), and to explore the risk factors affecting 28-day all-cause mortality.

methodOur retrospective analysis was conducted on data from CRGNB-HAP patients treated in the intensive care unit (ICU) with either intravenous polymyxin B alone or in conjunction with nebulized polymyxin B between November 28, 2018 and May 6, 2024. The primary endpoint was 28-day all-cause mortality, while safety outcomes were also assessed. Logistic regression analysis was utilized to identify the risk factors associated with 28-day all-cause mortality.

resultA total of 82 CRGNB-HAP patients were enrolled, including 38 patients in the intravenous plus nebulized (IV + NL) polymyxin B group and 44 patients in the intravenous (IV) polymyxin B group. The 28-day mortality rate of the IV + NL polymyxin B group was significantly lower than that of the IV polymyxin B group (23.7% vs 61.4%, p < 0.001), and there was no statistically significant difference in the incidence of acute kidney injury between the two groups. Multivariate logistic regression analysis indicated that IV + NL polymyxin B administration was a significant factor in reducing the 28-day mortality rate of CRGNB-HAP patients.

conclusionOur study found that intravenous combined with nebulized polymyxin B therapy is superior to intravenous monotherapy in the treatment of CRGNB-HAP, resulting in reduced 28-day mortality without increasing renal toxicity.

Indexed as

Anti-Bacterial AgentsGram-Negative BacteriaGram-Negative Bacterial InfectionsHealthcare-Associated PneumoniaPolymyxin BAdministration, InhalationAdministration, IntravenousAgedAged, 80 and overCarbapenemsDrug Therapy, CombinationFemaleHumansIntensive Care UnitsMaleMiddle AgedAnti-Bacterial AgentsCarbapenemsPolymyxin B28-day mortalityCarbapenem-resistant gram-negative bacilliHospital-acquired pneumoniaNebulized polymyxinsPolymyxin B

Identifiers

PMID40632377
PMCPMC12484255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.